FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

연구 용도로만 사용. 전체 공지 →

펩타이드 라이브러리

BPC-157

Body Protection Compound-157 / Bepecin / PL 14736 / PL-10

Recovery & Repair

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a protective protein found in human gastric juice. It is one of the most extensively researched peptides in preclinical models, with over 100 published studies demonstrating tissue-healing properties across tendons, ligaments, muscles, the gastrointestinal tract, and the nervous system. Despite robust animal data, no completed human clinical trials exist as of 2024.

작용 메커니즘

Pentadecapeptide derived from human gastric juice. Promotes angiogenesis via VEGF upregulation, accelerates tendon and ligament healing, modulates nitric oxide signaling, and protects endothelial cells. Demonstrates systemic healing properties across multiple tissue types.

연구 프로토콜

연구 용도만 사용 가능. 의학적 조언은 아닙니다.

Research protocols use 200-500mcg once or twice daily via subcutaneous injection near the injury site or systemically. Cycles of 4-12 weeks. Some protocols use oral administration at higher doses (500mcg-1mg).

연구 노트

Clinical Research Status

No completed human clinical trials. Extensive preclinical data across 100+ published studies in animal models. Currently being investigated by companies including Stabilitech Biopharma (oral formulation).

Key Published Findings

Demonstrated accelerated healing in rat models of Achilles tendon transection, medial collateral ligament rupture, and muscle crush injuries. Shown to promote angiogenesis (new blood vessel formation) through upregulation of VEGF and its receptor. Exhibits cytoprotective effects against NSAID-induced gastric damage in multiple studies.

Safety Profile

No significant toxicity reported in animal studies at standard research doses. No LD50 has been established (no lethal dose found). Remarkably wide safety margin in preclinical testing. Long-term human safety data does not exist.

Drug Interactions & Contraindications

May interact with dopaminergic and serotonergic systems. Shown to counteract the effects of dopamine agonists and antagonists in animal models. Potential interactions with medications affecting the nitric oxide system. Caution advised when combining with other growth-promoting compounds.

Comparison to Related Compounds

Often compared to and stacked with TB-500 (Thymosin Beta-4). BPC-157 tends to be more localized in its healing effects while TB-500 is more systemic. Unlike most peptides, BPC-157 is stable at gastric pH, enabling oral administration without significant degradation.

Community Observations

Widely used in the biohacking and athletic recovery community. Anecdotal reports consistently describe accelerated recovery from soft tissue injuries. Some users report improved gut function and reduced inflammation. Injection site reactions are the most commonly reported side effect.

반감기

~4 hours

재조성

Bacteriostatic water (BAC)

보관

건조한 상태

Refrigerate 2-8C up to 24 months. Protect from light.

재조성된 상태

Refrigerate 2-8C. Use within 14 days.

미국 법적 상태

Research chemical (not FDA-approved)

또는 알려진 이름으로

Body Protection Compound-157BepecinPL 14736PL-10

자주 묻는 질문

BPC-157란 무엇인가요?

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a protective protein found in human gastric juice. It is one of the most extensively researched peptides in preclinical models, with over 100 published studies demonstrating tissue-healing properties across tendons, ligaments, muscles, the gastrointestinal tract, and the nervous system. Despite robust animal data, no completed human clinical trials exist as of 2024.

BPC-157는 어떻게 작용하나요?

Pentadecapeptide derived from human gastric juice. Promotes angiogenesis via VEGF upregulation, accelerates tendon and ligament healing, modulates nitric oxide signaling, and protects endothelial cells. Demonstrates systemic healing properties across multiple tissue types.

BPC-157의 미국 규제 현황은 어떤가요?

Research chemical (not FDA-approved)

BPC-157의 반감기는 얼마인가요?

~4 hours

BPC-157의 다른 이름은 무엇인가요?

Body Protection Compound-157, Bepecin, PL 14736, PL-10

Peptide Contacts는 정보 제공을 위해 연구 기반 요약을 제공합니다. 우리는 공급업체 문서를 호스팅, 배포하거나 지지하지 않습니다. 모든 테스트 보고서, GMP 인증서 및 공급업체 통신은 구매자는 직접 요청하고 확인해야 합니다. 이 플랫폼에서 제공되는 어떠한 정보도 법적, 의학적 또는 전문적인 조언을 대체하지 않습니다. 사용자는 모든 관련 지역법, 주법 및 연방법에 부합하기 위해 공급업체 자격 증명을 검증하고 구매하기 전에 준수해야 합니다. 이 플랫폼의 사용은 이러한 책임을 완전히 지닌 것으로 간주됩니다.

전체 공지사항 읽기